Outlook Therapeutics, Inc. Stock price

Equities

OTLK

US69012T3059

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
11.94 USD +27.43% Intraday chart for Outlook Therapeutics, Inc. +69.60% +51.52%
Sales 2024 * 238K Sales 2025 * 11.85M Capitalization 202M
Net income 2024 * -72M Net income 2025 * -62M EV / Sales 2024 * 851 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 17.1 x
P/E ratio 2024 *
-3.58 x
P/E ratio 2025 *
-5.13 x
Employees 24
Yield 2024 *
-
Yield 2025 *
-
Free-Float 34.16%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Outlook Therapeutics, Inc.

1 day+27.43%
1 week+76.11%
Current month+36.68%
1 month+34.79%
3 months+29.05%
6 months+174.86%
Current year+51.52%
More quotes
1 week
7.70
Extreme 7.7
12.70
1 month
5.04
Extreme 5.0401
12.70
Current year
5.04
Extreme 5.0401
12.70
1 year
4.00
Extreme 4.004
40.60
3 years
4.00
Extreme 4.004
65.40
5 years
4.00
Extreme 4.004
174.00
10 years
4.00
Extreme 4.004
878.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 66 21-07-06
Director of Finance/CFO 58 15-09-14
Chief Tech/Sci/R&D Officer - 23-01-18
Members of the board TitleAgeSince
Chairman 74 18-04-12
Director/Board Member 63 15-12-10
Chief Executive Officer 66 21-07-06
More insiders
Date Price Change Volume
24-03-28 11.94 +27.43% 1,556,224
24-03-27 9.37 +7.95% 1,469,214
24-03-26 8.68 +2.00% 413,743
24-03-25 8.51 -1.39% 835,575
24-03-22 8.63 +22.59% 21,033,281

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
11.94 USD
Average target price
39.86 USD
Spread / Average Target
+233.81%
Consensus
  1. Stock
  2. Equities
  3. Stock Outlook Therapeutics, Inc. - Nasdaq